Figure 4.

PPCLs demonstrate heterogeneity in markers associated with cancer stemness and PC-immune cell interactions. A and B: PPCLs were evaluated for the cancer stem cell markers CD44, CD133 (A) and c-Met (B). The percentage of cells positive for both CD144 and CD33 are indicated in the rectangular gate. C: Immunohistochemical staining for PDL1 was performed on patient-derived xenografts from each patient. C–F: In addition, cell populations were analyzed for the expression of the negative costimulatory marker PDL1 (C), antigen presentation machinery (HLA-DR/DP/DQ; D), and the positive costimulatory markers CD80 (E) and CD86 (F). Histograms are shown for isotype controls (gray) and staining for the indicated marker (black). Scale bar = 200 μm (C). HLA, human leukocyte antigen; PDL1, programmed death ligand-1; PPLC, primary pancreatic cancer cell line.